November 13, 2013
This article was reported by Healio.
An article in Healio presents a study on the use of selective serotonin reuptake inhibitors (SSRIs) to treat depression resulting from the use of pegylated interferon alfa-2a or -2b (Peg-IFN a-2a or a-2b) with ribavirin combination treatment for chronic hepatitis C virus (HCV) infection. Peg-IFN a-2a or a-2b with ribavirin treatment is considered a very effective HCV treatment. However, this treatment is associated with a 70-percent incidence of mild to moderate depression and a 20- to 40-percent incidence of major depression in chronic HCV patients.
Researchers, including Yan-Yan Yu, MD, of the department of infectious diseases at China's Peking University, performed a meta-analysis of six randomized, double-blind, placebo-controlled trials with 522 chronic HCV patients who had received Peg-IFN a-2a or a-2b with ribavirin. Those participants who were treated with SSRIs received escitalopram, citalopram, or paroxetine.
The researchers concluded that treatment with SSRIs can reduce depression associated with Peg-IFN a-2a or a-2b with ribavirin treatment significantly for chronic HCV patients without reducing sustained virological response. The researchers noted study limitations such as unavailable data and small sample sizes.
The full report, "Can Antidepressants Prevent Pegylated Interferon-a/Ribavirin-Associated Depression in Patients with Chronic Hepatitis C: Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials?" was published online in the journal PLoS One (2013; doi: 10.1371/journal.pone.0076799).
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Expert: Long-Awaited CDC HIV Report on Conception Options for Serodiscordant Couples Is Disappointing and Confusing|
|The Best HIV Cure Will Be Built With Us, Not Just for Us|
|The Power of Positive Thinking Could Help Lower Viral Load|
|This Week in HIV Research: Stable Housing Improves Viral Suppression and CD4 Counts|
|The Curious Case of M184V, Part 1|
|Inflammation in the Brain Continues Even With Undetectable Plasma Viral Load|